Know Cancer

forgot password

A Phase II Trial Evaluating the Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site

Phase 2
18 Years
Not Enrolling
Carcinoma of Unknown Primary

Thank you

Trial Information

A Phase II Trial Evaluating the Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site

Carcinoma of unknown primary site (CUP) accounts for approximately 5% of all newly diagnosed
malignancies. The overall prognosis for patients with CUP remains poor, with median survival
less than one year with modern chemotherapy combinations and virtually no long-term

It has been recognized that patients with CUP represent a heterogeneous group of tumors.
Managing patients with CUP requires a complete medical history, careful consideration of
findings on physical exam, targeted radiologic studies and pathologic analysis of biopsy
and/or surgical specimens. Within this heterogeneous group there exist at least four subsets
of patients with CUP, that based on clinicopathologic features are treated with regimens
which have demonstrated efficacy in tumors originating in the most likely primary site of
that CUP; squamous carcinoma involving mid or high levels of cervical lymph nodes, women
with isolated axillary adenopathy containing adenocarcinoma, women with a predominant
presentation of peritoneal carcinomatosis and young men with extragonadal germ cell

Unfortunately, a majority of patients with CUP do not fall into any of the above subsets and
these represent a therapeutic dilemma, as there is no single regimen to date that has shown
significant activity or has resulted in prolonged survival for these patients with
particularly poor prognosis. Thus, new therapeutic combinations need to be investigated for
treatment of these patients with CUP.

Platinum compounds have been the cornerstone of chemotherapy regimens for a wide variety of
solid tumors, including lung, urothelial, head and neck, ovarian and endometrial carcinomas,
as well as testicular carcinomas. Cisplatin and its analog carboplatin are currently used in
chemotherapy combinations to treat CUP. Carboplatin has fewer non-hematologic side effects
compared to cisplatin including less nausea and vomiting, peripheral neuropathy,
nephrotoxicity and ototoxicity making it an attractive agent to combine with other drugs.

In recent years, new agents active in solid malignancies have been developed. Gemcitabine is
one such agent. It is a deoxycytidine analogue structurally related to cytosine
arabinoside. Gemcitabine is activated by deoxycytidine kinase in three steps of
phosphorylation into difluorodeoxycytidine triphosphate, which when incorporated into DNA,
leads to chain termination. Gemcitabine has been shown to have activity in pancreatic,
breast, non-small cell lung carcinomas as well as in carcinomas of unknown primary site.
Because of its mild toxicity profile, gemcitabine has been used in combination with other
chemotherapy agents. There is evidence of in vitro and in vivo synergy between gemcitabine
and the platinum compounds.

Capecitabine is an orally administered fluoropyrimidine that undergoes a three-step
conversion into 5-FU, with pharmacokinetics that mimic low dose continuous infusion 5-FU.
The oral formulation allows for convenient continuous therapy, avoiding a need for central
venous catheters and external infusion pumps.

The final step of conversion of capecitabine into 5-FU is catalyzed by thymidine
phosphorylase (TP), an enzyme which has been shown to be over expressed in colorectal
tumors. This selective tumor activation has been demonstrated to lead to higher
concentrations of 5-FU in tumor cells as compared to normal tissue, suggesting tumor
targeting by the oral drug. Capecitabine was initially approved by the FDA for treatment of
refractory breast carcinoma and has shown activity in metastatic colorectal carcinoma.
Capecitabine is an attractive agent for use in combination chemotherapy due to its
non-overlapping toxicity profile with many agents and lack of hematologic toxicity.

Gemcitabine has been combined with 5-FU, and may enhance the activity of 5-FU in vivo.
Gemcitabine is an inhibitor of ribonucleotide reductase, an enzyme needed for synthesis of
deoxynucleotides, and 5-FU interferes with dTTP synthesis by inhibition of thymidylate
synthase (TS). It is plausible that concomitant administration of gemcitabine and
capecitabine, may result in increased cytotoxicity by reducing intracellular dTTP thru two
different mechanisms, thereby inhibiting DNA replication and repair. Platinum compounds
lead to cell death by forming DNA adducts and causing double strand breaks. By inhibiting
DNA synthesis and repair, both gemcitabine and 5-FU analogues could potentiate the activity
of carboplatin. These interactions may underlie the clinical synergism that has been
observed with platinum/5-FU and platinum/gemcitabine combinations.

We propose to combine carboplatin, gemcitabine and capecitabine as a palliative treatment
for patients with CUP. Programs evaluating the incorporation of newer chemotherapy agents
into combinations are reasonable in an attempt to improve outcome in patients with CUP. In
addition to anticipated anti-tumor activity, the proposed combination provides a convenient
schedule of brief intravenous treatment, the use of the oral agent capecitabine, and a
toxicity profile which is expected to be mild, characteristics which are important in
palliative treatment programs.

Inclusion Criteria:

- Histologic or cytologic diagnosis of carcinoma, with clinical evidence of metastasis
and the primary site not clear after the following work-up:

- Complete history and physical

- Laboratory evaluation including serum beta-human chorionic gonadotropin (HCG),
serum alpha-fetoprotein for undifferentiated or poorly differentiated carcinomas
and serum prostate specific antigen (PSA) in men.

- Directed radiologic evaluation including, at a minimum, computerized tomography
(CT) of chest, abdomen and pelvis and bilateral mammography for female patients.

- Pathologic immunohistochemistry studies of the surgical or biopsy specimen,
including studies for estrogen receptor/progesterone receptor and PSA stains
when clinically appropriate.

- Patients must be at least 18 years of age and have a Zubrod performance status 0-2.

- Adequate organ function, defined as absolute neutrophil count (ANC) > 1500/ul,
platelet count of > 100,000/ul, serum creatinine less than or equal to 2.0 mg/dl,
serum bilirubin less than or equal to 1.5 mg/dl.

- Patients must have measurable disease. (Partial response [PR] - at least a 30%
decrease in the sum of LD of target lesions taking as reference the baseline sum LD.)

- Patients may be previously untreated or have received one chemotherapy regimen
provided it did not include carboplatin, gemcitabine or capecitabine.

- Patients must have no serious intercurrent medical or psychiatric illness that would
limit their ability to provide informed consent or receive protocol therapy.

- Patients must be informed of the investigational nature of this study and provide
written informed consent in accordance with institutional and federal guidelines
prior to the initiation of therapy.

Exclusion Criteria:

- Patients with previous invasive malignancy within the preceding 5 years are
ineligible unless clinicopathologic information regarding the current neoplasm is
clearly discordant from prior disease. Patients with non-melanoma skin cancer or in
situ cancer of any site are eligible.

- Patients with brain metastasis are not eligible.

- No concurrent chemotherapy, biological or radiotherapy is allowed.

- Pregnant or lactating women are not eligible. Women and men of childbearing
potential must agree to use effective contraception throughout the treatment period,
and for six months after treatment has been discontinued.

- The following groups of patients will not be eligible for the study as they represent
populations of patients with CUP for whom more specific treatment approaches are

1. Patients presenting with squamous carcinoma isolated to middle and high
cervical lymph nodes

2. Women presenting with isolated axillary lymphadenopathy

3. Women presenting with predominant peritoneal carcinomatosis

4. Men < 50 years of age presenting with predominant mediastinal and/or
retroperitoneal nodal involvement and biopsy showing undifferentiated or poorly
differentiated carcinoma.

Type of Study:


Study Design:

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label

Principal Investigator

Mark Zalupski, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Michigan Cancer Center


United States: Institutional Review Board

Study ID:

UMCC 2001-021



Start Date:

May 2001

Completion Date:

October 2007

Related Keywords:

  • Carcinoma of Unknown Primary
  • Carcinoma of Unknown Primary Site (CUP)
  • Carcinoma
  • Neoplasms, Unknown Primary



University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan  48109-0752